The online version of this article (doi:10.1186/1752-1947-8-69) contains supplementary material, which is available to authorized users.
The authors declare they have no competing interests.
SA managed the patient, gathered the data, searched and reviewed the literature. AE searched and reviewed the literature and critically shared in the design and finishing the manuscript. Both authors read and approved the final manuscript.
Erythromelalgia is a rare clinical syndrome characterized by episodic erythema, warmth and intense burning pain, which commonly involves the extremities. For those affected, this disorder may lead to significant long-term morbidity. Unfortunately, to date, no definitive therapy is available. This case report describes an Egyptian child with primary erythromelalgia that manifested at an early age and showed partial response to therapy with cetirizine hydrochloride. This anecdotal case report may have a diagnostic value for clinicians who have not seen this disorder.
A 34-month-old previously healthy right-handed Hamitic boy without any significant past medical history presented at the age of 2 years with episodic bilateral pain in his feet. His mother reported associated warmth and erythema localized to his feet that never extended beyond his ankle joints. This pain is triggered by exertion and/or warm temperature exposure and is relieved by cooling measures. The diagnosis of erythromelalgia was made based on the patient’s medical history and a thorough physical examination during the episodes. No evidence of local or systemic infection was present. Other causes for the symptoms were excluded by a negative extensive diagnostic work-up. Our patient did not respond to ibuprofen (15mg/kg/dose) three times a day but partial improvement with the oral non-sedating antihistaminic cetirizine hydrochloride (2.5mg/kg/once daily) was observed. When the child stopped cetirizine hydrochloride for 1 month as a test, the symptoms became aggravated and were relieved when cetirizine therapy was restarted. Cetirizine hydrochloride had not previously been reported to have this effect in children with erythromelalgia.
Erythromelalgia is a clinical syndrome of which the etiology, diagnosis and management are controversial. We describe a case of a 34-month-old Egyptian child with primary erythromelalgia that manifested at an early age. We believe that this is the first Egyptian case report of this kind in the literature. Partial response of this patient to cetirizine hydrochloride may grant us a new clue to understanding this mysterious condition.
Mitchell SW: On a rare vasomotor neurosis of the extremities and on the maladies with which it may be confounded. Am J Med Sci. 1878, 76: 17-36. CrossRef
Cook-Norris RH, Tollefson MM, Cruz-Inigo AE, Sandroni P, Davis MD, Davis DM: Pediatric erythromelalgia: a retrospective review of 32 cases evaluated at Mayo clinic over a 37-year period. J Am Acad Dermatol. 2011, 26:
Estacion M, Dib-Hajj SD, Benke PJ, te Morsche RH, Eastman EM, Macala LJ, Drenth JP, Waxman SG: Na v1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci. 2008, 28: 11079-11088. 10.1523/JNEUROSCI.3443-08.2008. CrossRefPubMed
Kvernebo K: Erythromelalgia – a condition caused by microvascular arteriovenous shunting. Vasa. 1998, 51 (Suppl): 1-39.
Min-Tzu W, Po-Yuan H, Chen-Tung Y, Chih-Cheng C, Ming-Jen L: A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers. PLoS One. 2013, 8: e55212-10.1371/journal.pone.0055212. CrossRef
Legroux-Crespel E, Sassolas B, Guillet G: Treatment of familial erythermalgia with the association of lidocaine and mexiletine. Ann Dermatol Venereol. 2003, 130: 429-433. PubMed
Goldberg YP, Price N, Namdari R, Cohen CJ, Lamers MH, Winters C, Price J, Young CE, Verschoof H, Sherrington R, Pimstone SN, Hayden MR: Treatment of Na v1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012, 153: 80-85. 10.1016/j.pain.2011.09.008. CrossRefPubMed
Yang Y, Dib-Hajj SD, Zhang J, Zhang Y, Tyrrell L, Estacion M, Waxman SG: Structural modeling and mutant cycle analysis predict pharmacoresponsiveness of a Na v1.7 mutant channel. Nature Comm. 2012, 3: 1186- CrossRef
The erythromelalgia association: footSteps: toward progress. Newsletter. 2006, 7: 6- http://www.erythromelalgia.org,
- An Egyptian child with erythromelalgia responding to a new line of treatment: a case report and review of the literature
Samir M Al-Minshawy
Abdel-Azeem M El-Mazary
- BioMed Central